A retrospective cohort study of chimeric antigen receptor T-Cell therapy in follicular lymphoma patients with or without histological transformation.

IF 2.4 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2025-06-01 Epub Date: 2025-06-02 DOI:10.1007/s00277-025-06428-5

Jingjing Wang, Liangyu Zeng, Xiao Ma, Ting Xu, Depei Wu, Caixia Li

{"title":"A retrospective cohort study of chimeric antigen receptor T-Cell therapy in follicular lymphoma patients with or without histological transformation.","authors":"Jingjing Wang, Liangyu Zeng, Xiao Ma, Ting Xu, Depei Wu, Caixia Li","doi":"10.1007/s00277-025-06428-5","DOIUrl":null,"url":null,"abstract":"Background: Follicular lymphoma (FL), one of the most common indolent lymphomas, is still classified as an incurable disease. Adverse outcomes in FL frequently occur in patients who experience early relapse or histological transformation to aggressive lymphoma. Chimeric antigen receptor T-cell therapy (CAR-T) has received approval for the treatment of relapsed/refractory B-cell lymphoma.Methods: This retrospective study presents the clinical characteristics and treatment follow-up of 26 patients with transformed or relapsed/refractory FL who received CAR-T therapy. It evaluates the efficacy of CAR-T and assesses treatment lines, LDH levels, remission status before treatment, and the histological transformation of their prognostic impact.Results: Among the 14 transformed FL patients, there was one treatment-related death, the overall response rate (ORR) was 92.0%, with a 2-year progression-free survival (PFS) rate of 66.7% and an overall survival (OS) rate of 73.3%. For the 12 relapsed/refractory FL patients, the ORR was 100.0%, with a 2-year PFS rate of 75.0% and an OS rate of 100.0%, which is higher than that for transformed FL. A favorable remission state before CAR-T treatment correlated with improved PFS (P = 0.009). Compared to transformed patients, those with relapsed/refractory FL exhibited better OS following CAR-T treatment (P = 0.04).Conclusion: CAR-T therapy shows significant efficacy and safety for treating relapsed/refractory follicular lymphoma and transformed lymphoma. Further research should focus on identifying prognostic factors, extending remission duration, and preventing recurrence.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3309-3317"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283427/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06428-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Follicular lymphoma (FL), one of the most common indolent lymphomas, is still classified as an incurable disease. Adverse outcomes in FL frequently occur in patients who experience early relapse or histological transformation to aggressive lymphoma. Chimeric antigen receptor T-cell therapy (CAR-T) has received approval for the treatment of relapsed/refractory B-cell lymphoma.

Methods: This retrospective study presents the clinical characteristics and treatment follow-up of 26 patients with transformed or relapsed/refractory FL who received CAR-T therapy. It evaluates the efficacy of CAR-T and assesses treatment lines, LDH levels, remission status before treatment, and the histological transformation of their prognostic impact.

Results: Among the 14 transformed FL patients, there was one treatment-related death, the overall response rate (ORR) was 92.0%, with a 2-year progression-free survival (PFS) rate of 66.7% and an overall survival (OS) rate of 73.3%. For the 12 relapsed/refractory FL patients, the ORR was 100.0%, with a 2-year PFS rate of 75.0% and an OS rate of 100.0%, which is higher than that for transformed FL. A favorable remission state before CAR-T treatment correlated with improved PFS (P = 0.009). Compared to transformed patients, those with relapsed/refractory FL exhibited better OS following CAR-T treatment (P = 0.04).

Conclusion: CAR-T therapy shows significant efficacy and safety for treating relapsed/refractory follicular lymphoma and transformed lymphoma. Further research should focus on identifying prognostic factors, extending remission duration, and preventing recurrence.

查看原文本刊更多论文

嵌合抗原受体t细胞治疗伴或不伴组织学转变的滤泡性淋巴瘤患者的回顾性队列研究。

背景：滤泡性淋巴瘤（滤泡性淋巴瘤）是最常见的惰性淋巴瘤之一，仍被归类为不治之症。恶性淋巴瘤的不良后果经常发生在早期复发或组织学转变为侵袭性淋巴瘤的患者身上。嵌合抗原受体t细胞疗法（CAR-T）已被批准用于治疗复发/难治性b细胞淋巴瘤。方法：回顾性分析26例接受CAR-T治疗的转化性或复发/难治性FL患者的临床特点及治疗随访。它评估CAR-T的疗效，并评估治疗线、LDH水平、治疗前的缓解状态，以及它们对预后影响的组织学转变。结果：14例转化性FL患者中，治疗相关死亡1例，总缓解率（ORR）为92.0%，2年无进展生存（PFS）率为66.7%，总生存（OS）率为73.3%。12例复发/难治性FL患者的ORR为100.0%，2年PFS率为75.0%，OS率为100.0%，高于转化性FL患者。CAR-T治疗前良好的缓解状态与PFS改善相关（P = 0.009）。与转化患者相比，CAR-T治疗后复发/难治性FL患者表现出更好的OS （P = 0.04）。结论：CAR-T治疗复发/难治性滤泡性淋巴瘤和转化性淋巴瘤疗效显著，安全性高。进一步的研究应集中于确定预后因素、延长缓解期和预防复发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.